Skip to content
ApprovedFDA approved

Anastrozole (Arimidex)

Prescription aromatase inhibitor for breast cancer that bodybuilders also use to lower estrogen; banned on the doping list.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Anastrozole (Arimidex) vial

DETAILED OVERVIEW

What is Anastrozole (Arimidex)?

Anastrozole (Arimidex) is a prescription aromatase inhibitor: it blocks the enzyme that turns male hormones into estrogen. In the United States it has been approved since 1995 for treating estrogen-sensitive breast cancer after menopause, and it is registered in Hungary and Poland as well. Bodybuilders and athletes also use it off-label, to keep estrogen low during steroid use and so avoid breast growth and water retention.

Pushing estrogen down too far, however, can cause joint and muscle pain, loss of sex drive, erection problems, low mood and sleep problems. It worsens cholesterol values, and with longer use it lowers bone density and raises the risk of fractures. It must not be used in pregnancy or breastfeeding, because it can cause fetal harm and miscarriage. On the anti-doping list, aromatase inhibitors are banned for male athletes both in and out of competition.

Mechanism

Reversible aromatase inhibitor; lowers estrogen levels by over 90%

Half-life

~50 hours (single daily dose, steady-state day 7)

Onset

E2 reduction measurable 24-48 h, full effect 5-7 days

Legal status

FDA + EMA Rx, HU + PL approved, WADA S4.1 banned

Data console

Lab data

Androgenic:AnabolicN/A (not AAS, AI)
AR bindingCYP19 aromatase active-site competitive binding, Ki ~10-15…
Active half-lifeN/A (parent compound active, metabolites inactive)
Detection windowWADA-accredited GC-MS/LC-MS/MS urine detection 1-2 months post-last dose (parent + glucuronide metabolite markers).
AromatizationDoes not aromatize – competitive CYP19 aromatase inhibitor (IC50 ~15 nM in vitro, ~97% serum E2 suppression at 1 mg/day). Anastrozole itself is NOT a substrate of aromatase; it binds directly to the substrate-binding site.
HepatotoxicityLow – non-steroidal, NOT 17α-alkylated. FDA Arimidex label: rare ALT/AST elevations (<2% incidence), clinically significant hepatotoxicity extremely rare. Long-term female adjuvant use (5+ years) shows no significant liver injury pattern (ATAC 10-year follow-up).

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Joint and muscle pain (arthralgia, myalgia), a common AI side effect, especially wrists, knees and hands, pronounced when E2 is over-suppressed
  • Excessive estrogen suppression (crashed E2): loss of libido, erectile dysfunction, lethargy, depressed mood, sleep disturbance
  • Adverse lipid profile: HDL decrease (~10-20%) and LDL rise, long-term cardiovascular risk, lipid monitoring required
  • Reduced bone mineral density (osteopenia, osteoporosis) and fracture risk from chronic E2 deficit, DEXA monitoring advised with long-term use
  • Hot flushes and sweating, a characteristic vasomotor symptom of estrogen suppression (common in clinical trials)
  • Fatigue, headache and nausea; rarely mild, transient ALT/AST elevation (<2% incidence, serious hepatotoxicity extremely rare)
  • Skin rash and rarely severe skin reactions (erythema multiforme, Stevens-Johnson syndrome described on the FDA label), allergic reactions

Contraindications · 7

  • Pregnancy and breastfeeding are absolute contraindications (FDA Pregnancy Category X) – risk of fetal harm and pregnancy loss, contraception mandatory in women of childbearing potential
  • Premenopausal women: anastrozole is ineffective and not indicated, as ovarian aromatase activity is not adequately suppressed, causing hormonal dysfunction
  • Known hypersensitivity to anastrozole or any excipient (allergic reaction)
  • Severe hepatic insufficiency (Child-Pugh C): CYP3A4/CYP1A2 metabolism is impaired, clinical data lacking, avoid
  • Pre-existing osteoporosis or severe bone loss: chronic E2 suppression further worsens bone density and raises fracture risk
  • Concurrent tamoxifen or estrogen-containing agents: tamoxifen lowers anastrozole plasma levels and estrogens negate the treatment, combination should be avoided
  • Significantly adverse cardiovascular/lipid status (ischaemic heart disease, uncontrolled dyslipidemia): the AI can further worsen the lipid profile, close monitoring or avoidance warranted

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Anastrozole (Arimidex)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.